 |
17 Diseases |  |
1 Trial |
|
1 Trial |  |
43 News |  |
- | Journal: Identification of critical genes and metabolic pathways in rheumatoid arthritis and osteoporosis toward drug repurposing. (Pubmed Central) - Aug 27, 2024
The results of the present study can provide novel insights into the pathogenesis and treatment of RA and OP.
- vadimezan (ASA404) / Antisoma
Augmenting Post-Surgical Tumor Immune Response and Recurrence Prevention via Nanoparticle-Assisted Targeted Drug Delivery (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1487;
Methods : FP/Vad@CC-aT2, a biomimetic nanoparticle system containing FePt and Vadimezan, was prepared via extrusion and conjugated with anti-Trem2 antibodies...Conclusions : The study developed FP/Vad@CC-aT2, a targeted delivery system with good biocompatibility and significant antitumor effects. It was found to promote immune remodeling, induce immunogenic cell death, and alter immune cell composition in post-surgical relapse mouse models, suggesting its potential in preventing postoperative relapse and providing a basis for clinical applications.
- | 5-fluorouracil / Generic mfg.
Journal: Integrated anti-vascular and immune-chemotherapy for colorectal carcinoma using a pH-responsive polymeric delivery system. (Pubmed Central) - Jun 9, 2024
levels in serum. Therefore, this research introduces a pH-responsive polymer-based theranostic platform with great potential for immune-chemotherapeutic and anti-vascular combination therapy of CRC.
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Cabozantinib induces mtDNA-dependent cytotoxicity through cGas-STING signaling in experimental hepatocellular carcinoma (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1529;
Cabozantinib-induced mtDNA leakage to the cytosol induces ISGs signaling by activating the cGas-STING pathway in hepatoma cells. Our results reveal mitochondrial damage and the mtDNA-cGas-STING axis as compelling targets in antitumor efficacy with a potential role in immunological responses.
- vadimezan (ASA404) / Antisoma
Engineering cell membrane nanoparticlesenhance immunotherapy and radiodynamic therapy for lung adenocarcinoma by promoting cGAS-STING and ferroptosis (Section 20) - Mar 5, 2024 - Abstract #AACR2024AACR_7625;
We conducted preliminary experiments in vitro and in vivo to validate its physicochemical properties and tumor inhibitory effects, including the induction of ferroptosis. We assessed its safety in mouse and obtained initial evidence of FP/Vad@CC-aT2's ability to remodel the subtypes of macrophage.Moving forward, we will validate its therapeutic and impact on the TME after surgical procedures.
- vadimezan (ASA404) / Antisoma
Radiation and STING activation limit tumor development and modulate the immune environment via distinct mechanisms (Section 24; Poster Board #19) - Mar 14, 2023 - Abstract #AACR2023AACR_8504;
In this study, we examined the effect of radiation and the STING agonist, DMXAA (Vadimezan), on the development of urethane-induced lung cancer.A/J mice were treated with urethane (i.p.) to induce the development of lung tumors...The different outcomes of RT and DMXAA on tumor growth may be driven by their distinctive mechanism of action on immune responses and capacities to form TLSs. These findings may have future implications for strategies for the early treatment of lung and other cancers, and they suggest that immune responses, including modulation of the STING pathway, may be an important aspect of early tumor development that could be targeted therapeutically.
- | vadimezan (ASA404) / Antisoma
Journal, Checkpoint inhibition, Checkpoint block: Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer. (Pubmed Central) - Feb 27, 2023
The synthesized nanodroplet consisted of a O-filled Perfluorohexane (PFH) core and a lipid membrane carrying sonosensitizer IR-780 and STING agonist Vadimezan (DMXAAs)...However, the hypoxic tumor microenvironment severely restricts the therapeutic efficiency of SDT, wherein, oxygen is indispensable in the process of ROS generation. Here, we report an O-filled nanodroplet-enhanced sonodynamic therapy that significantly potentiated immune checkpoint blockade for systemic suppression of TNBC.
- | vadimezan (ASA404) / Antisoma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer. (Pubmed Central) - Oct 1, 2022
The efficacy could be further improved when LV-sHDL was used in combination with antibody against programmed cell death ligand 1. This study highlights the combination use of multitargeted TKI and STING agonist a promising treatment for metastatic TNBC.
- | vadimezan (ASA404) / Antisoma
Journal: Phytochemistry, biological activities and in silico molecular docking studies of Oxalis pes-caprae L. compounds against SARS-CoV-2. (Pubmed Central) - Jun 28, 2022
This work provide justification about this plant as a source of effective phytochemicals and their potential against microbes could lead to development of biosafe drugs for the welfare of human being. In future, different in vitro and in vivo biological studies can be performed to further investigate its biomedical potentials.
- | vadimezan (ASA404) / Antisoma, PR104 / Proacta
Journal: Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. (Pubmed Central) - Apr 5, 2022
Inclusion of the pre-prodrug PR-104 into the treatment schedule provided significant additional activity, indicating proof-of-principle. Successful preclinical evaluation of a transferable gene that enables metabolism of both PET imaging agents (for vector visualisation) and prodrugs (for conditional enhancement of efficacy) is an important step towards the prospect of CDEPT entering clinical evaluation.
- | vadimezan (ASA404) / Antisoma
Journal: Synthesis and Properties of α-Mangostin and Vadimezan Conjugates with Glucoheptoamidated and Biotinylated 3rd Generation Poly(amidoamine) Dendrimer, and Conjugation Effect on Their Anticancer and Anti-Nematode Activities. (Pubmed Central) - Mar 27, 2022
This effect was significantly enhanced after conjugation of the drug with the dendrimer via the amide, but not the ester bond, with G3 inhibiting the proliferation of SCC-15 and U-118 MG cells at concentrations ≥4 and ≥12 μM, respectively, without a visible effect in normal BJ cells. Thus, the drug delivery system based on the PAMAM G3 dendrimer containing amide bonds, partially-blocked amino groups on the surface, larger particle diameter and higher zeta potential can be a useful tool to improve the biological properties of transported drug molecules.
- || vadimezan (ASA404) / Antisoma
Review, Journal: Flavonoid-Inspired Vascular Disrupting Agents: Exploring Flavone-8-Acetic Acid and Derivatives in the New Century. (Pubmed Central) - Sep 19, 2021
Consequently, in the last decade a renewal of interest for these flavonoid-based structures was noticed, and novel derivatives have been synthesised and evaluated for a deeper understanding of the molecular features needed for affecting human cells. Undoubtedly, these natural-derived molecules deserve further investigation and still appear attractive in an anticancer perspective.
- | vadimezan (ASA404) / Antisoma
Journal: A Highly-Efficient Type I Photosensitizer with Robust Vascular-Disruption Activity for Hypoxic-and-Metastatic Tumor Specific Photodynamic Therapy. (Pubmed Central) - Jun 24, 2021
Simultaneously, the efficient ester-bond hydrolysis of BDPVDA in the acidic tumor microenvironment allows vadimezan release from PBV NPs to disrupt vasculature, facilitating the shut-down of metastatic pathways. As a result, PBV NPs will not only be powerful in resolving the paradox between traditional type II PDT and hypoxia, but also successfully prevent tumor metastasis after type I PDT treatment (no secondary-tumors found in 70 days and 100% survival rate), enabling enhancement of existing hypoxic-and-metastatic tumor treatment.
- | vadimezan (ASA404) / Antisoma
Journal: Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. (Pubmed Central) - Jun 1, 2021
In situ activated platelets generate aPDL1-decorated platelet-derived microparticles (PMP) that diffuse within the tumour and elicit immune responses. The proposed combination increases 10-fold aPDL1 antibody accumulation in lung metastases as compared to the intravenous administration of the antibody and enhances the magnitude of immune responses leading to improved antitumour effects.
- | vadimezan (ASA404) / Antisoma
Preclinical, Journal: Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice. (Pubmed Central) - Apr 22, 2021
The tCoa-NGR induce thrombosis which reduces blood flow in the peripheral tumor region. And combined with the action of DMXAA, which target inner tumor mass, growth and proliferation of melanoma tumors can be significantly suppressed.
- || vadimezan (ASA404) / Antisoma
Clinical, Journal: The Association Analysis of GPNMB rs156429 With Clinical Manifestations in Chinese Population With Parkinson's Disease. (Pubmed Central) - Sep 30, 2020
This study revealed that GPNMB rs156429 might have a trend for being associated with cognitive dysfunction and pain symptoms of female PD patients in the southeastern Chinese population. Further studies from a larger sample size are needed to confirm these findings.
- | vadimezan (ASA404) / Antisoma
Journal: Association of OPG gene polymorphisms with the risk of knee osteoarthritis among Chinese people. (Pubmed Central) - Jun 29, 2020
Our results verify that genetic variants of OPG contribute to knee OA susceptibility in the population of northern China. These genetic associations may identify individuals at a particularly high risk of developing knee OA.
- | vadimezan (ASA404) / Antisoma
Journal: Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. (Pubmed Central) - May 19, 2020
Replacement of vadimezan with the chemotherapeutic mertansine potentiated ICD of HCC cells, but the drug interfered with DC maturation and subsequent CD8+ T cell priming, resulting in unsatisfactory disease control. Our work provides a generalizable nanoplatform for combined photothermal ablation and immunotherapy of HCC and highlights the importance of cancer cell-specific ICD induction and simultaneous DC activation during in situ vaccination.
- | vadimezan (ASA404) / Antisoma
Journal: Identification of α-Mangostin as A Potent Agonist of Human STING. (Pubmed Central) - Sep 18, 2019
The xanthone derivate 5',6'-dimethylxanthenone-4-acetic acid (DMXAA, also known as ASA404 or vadimezan) is a potent agonist of murine STING (stimulator of interferon genes), but cannot activate human STING...Furthermore, our studies show that α-Mangostin has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype. The agonist effect of α-Mangostin in the STING pathway might account for its antitumor and antivirus bioactivities.
- | vadimezan (ASA404) / Antisoma
Review, Journal: An overview on Vadimezan (DMXAA), the vascular disrupting agent. (Pubmed Central) - Jul 24, 2019
The reason for this surprising discrepancy, among others, was discovered to be STING receptor variations between mice and humans. In this review, the development, the mechanisms of DMXAA action, the clinical trials, the combination therapy, and the future of this drug will be discussed.
- ||| vadimezan (ASA404) / Antisoma, selumetinib (AZD6244) / Merck (MSD), AstraZeneca
P2 data, P3 data: One of the more dramatic examples of promising phase 2 trials that flamed out in phase 3 & should be humbling reminders before we get too breathless over the next encouraging ph 2. See also ASA-404, selumetinib w/docetaxel, consol docetaxel, ...we need to keep a master list. (Twitter) - Jul 18, 2019
- | vadimezan (ASA404) / Antisoma
Journal: Activation of Stimulator of Interferon Genes (STING) and Sjögren Syndrome. (Pubmed Central) - Jun 26, 2019
Our study demonstrates that activation of the STING pathway holds the potential to initiate SS. Thus, apart from viral infections, conditions that cause cellular perturbations and accumulation of host DNA within the cytosol should also be considered as possible triggers for SS.
- vadimezan (ASA404) / Antisoma
Trial termination, Metastases: A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors (clinicaltrials.gov) - Apr 21, 2016
P1, N=7, Terminated, Sponsor: Novartis Pharmaceuticals
Thus, apart from viral infections, conditions that cause cellular perturbations and accumulation of host DNA within the cytosol should also be considered as possible triggers for SS. Completed --> Terminated
- vadimezan (ASA404) / Antisoma
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma (clinicaltrials.gov) - Aug 19, 2015
P2, N=0, Withdrawn, Sponsor: Hoosier Cancer Research Network
Completed --> Terminated N=40 --> 0 | Suspended --> Withdrawn | Trial primary completion date: May 2011 --> Jun 2010
- |||| vadimezan (ASA404) / Antisoma
Trial completion, Combination therapy, Metastases: Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=70, Completed, Sponsor: Antisoma Research
N=40 --> 0 | Suspended --> Withdrawn | Trial primary completion date: May 2011 --> Jun 2010 No longer recruiting --> Completed
- vadimezan (ASA404) / Antisoma
Trial completion: Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors (clinicaltrials.gov) - Dec 17, 2013
P1, N=3, Completed, Sponsor: University of Glasgow
No longer recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, vadimezan (ASA404) / Antisoma
Enrollment change, Combination therapy: ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - May 8, 2013
P1, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=24 --> 0
- vadimezan (ASA404) / Antisoma
Enrollment change: SAKK 15/08: Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - Jul 30, 2012
P2, N=17, Completed, Sponsor: Swiss Group for Clinical Cancer Research
N=24 --> 0 N=57 --> 17
- vadimezan (ASA404) / Antisoma
Trial completion: SAKK 15/08: Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - Jul 30, 2012
P2, N=17, Completed, Sponsor: Swiss Group for Clinical Cancer Research
N=57 --> 17 Active, not recruiting --> Completed